oral Akt inhibitor
Ph. I in advanced solid tumors
scaffold hopping and PK opt.
J. Med. Chem.
Nanjing Chia-Tai Tianqing Pharmaceutical Co., Ltd., Nanjing, CN
Context. NTQ1062 (Nanjing Chia-Tai Tianqing; CTTQ) is an oral ATP-competitive Akt inhibitor being developed for cancer. Because the PI3K/Akt/mTOR pathway is one of the most commonly disrupted pathways in…